Biogen Inc. (BIIB) KPIs and segments
Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Biogen · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)
Nhìn nhanh KPI của Biogen: 56 chỉ số vận hành, trong đó có Growth Portfolio Revenue, Total Consolidated Revenue và Total Product Revenue, Net, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product revenue, net($M)2 | 2,089 | 1,916 | 1,752 | 1,667 | 1,847 | 1,879 | 1,727 | 1,833 | 1,769 | 1,900 | 1,712 | 1,832 | |
U. S.($M) | 1,265 | 1,115 | 839 | 918 | 935 | 941 | 754 | 832 | 813 | 847 | 746 | 848 | |
Rest of World($M) | 824 | 802 | 913 | 750 | 912 | 938 | 973 | 1,001 | 956 | 1,053 | 966 | 984 | |
MS Product Revenues($M)2 | 919 | 963 | 958 | 917 | 1,062 | 1,107 | 953 | 1,070 | 1,054 | 1,150 | 1,076 | 1,168 | |
U. S.($M) | 584 | 621 | 559 | 582 | 643 | 657 | 490 | 559 | 546 | 582 | 503 | 621 | |
Rest of World($M) | 335 | 342 | 398 | 335 | 419 | 450 | 463 | 511 | 508 | 567 | 573 | 547 | |
Rare Disease Product Revenue($M)2 | 676 | 602 | 557 | 515 | 533 | 543 | 563 | 535 | 495 | 534 | 424 | 472 | |
U. S.($M) | 354 | 295 | 225 | 265 | 235 | 235 | 231 | 244 | 240 | 238 | 226 | 217 | |
Rest of World($M) | 322 | 307 | 333 | 249 | 298 | 308 | 332 | 291 | 254 | 297 | 198 | 255 | |
Revenue from anti-CD20 therapeutic programs($M) | 497 | 514 | 419 | 494 | 467 | 378 | 446 | 445 | 394 | ||||
SPINRAZA($M)2 | 461 | 402 | 374 | 356 | 374 | 393 | 424 | 421 | 381 | 429 | 341 | 413 | |
U. S.($M) | 246 | 204 | 142 | 169 | 153 | 149 | 154 | 167 | 153 | 157 | 149 | 158 | |
Rest of World($M) | 214 | 198 | 232 | 188 | 221 | 243 | 270 | 255 | 228 | 272 | 193 | 255 | |
TYSABRI($M)2 | 437 | 451 | 442 | 398 | 432 | 455 | 382 | 415 | 406 | 462 | 431 | 465 | |
U. S.($M) | 253 | 271 | 242 | 245 | 248 | 272 | 201 | 230 | 228 | 249 | 214 | 248 | |
Rest of World($M) | 184 | 180 | 200 | 153 | 184 | 182 | 181 | 185 | 179 | 214 | 218 | 217 | |
Royalty Attributed To OCREVUS($M) | 370 | 381 | 317 | 386 | 386 | 354 | 289 | 354 | 347 | 336 | 303 | 338 | |
Fumarate($M)2 | 274 | 287 | 289 | 293 | 383 | 406 | 345 | 404 | 391 | 418 | 382 | 401 | |
U. S.($M) | 198 | 204 | 185 | 193 | 234 | 235 | 157 | 195 | 175 | 188 | 150 | 203 | |
Rest of World($M) | 76.1 | 83 | 104 | 99.5 | 149 | 171 | 188 | 210 | 216 | 230 | 232 | 197 | |
Specialized Immunology($M)2 | 243 | 128 | 0 | 0 | |||||||||
U. S.($M) | 243 | 128 | 0 | 0 | |||||||||
Rest of World($M) | 0 | 0 | 0 | 0 | |||||||||
Interferon($M)2 | 208 | 225 | 228 | 226 | 247 | 247 | 226 | 236 | 238 | 251 | 244 | 280 | |
U. S.($M) | 133 | 146 | 133 | 144 | 161 | 150 | 133 | 134 | 144 | 145 | 140 | 170 | |
Rest of World($M) | 75 | 79 | 94.7 | 81.8 | 85.7 | 96.7 | 93.6 | 102 | 94 | 106 | 104 | 110 | |
VUMERITY($M)2 | 192 | 197 | 179 | 181 | 215 | 212 | 139 | 177 | 158 | 166 | 128 | 156 | |
U. S.($M) | 167 | 172 | 153 | 157 | 190 | 188 | 117 | 154 | 135 | 144 | 106 | 140 | |
Rest of World($M) | 25.3 | 24.5 | 25.6 | 24.6 | 25 | 24.3 | 21.7 | 23 | 23.2 | 21.6 | 21.6 | 16.9 | |
SYFOVRE($M)2 | 191 | 97.4 | 0 | 0 | |||||||||
U. S.($M) | 191 | 97.4 | 0 | 0 | |||||||||
Rest of World($M) | 0 | 0 | 0 | 0 | |||||||||
SKYCLARYS($M)2 | 178 | 168 | 151 | 133 | 133 | 130 | 124 | 102 | 102 | 100 | 78 | 55.9 | |
U. S.($M) | 97.2 | 82.3 | 71.8 | 88.9 | 74.6 | 78 | 69.1 | 70.7 | 81.8 | 75.6 | 73 | 55.9 | |
Rest of World($M) | 81 | 85.6 | 78.9 | 44.5 | 58.3 | 52.3 | 54.8 | 31.5 | 20.5 | 24.4 | 5 | 0 | |
Biosimilars($M)2 | 166 | 153 | 182 | 170 | 197 | 182 | 181 | 202 | 197 | 198 | 197 | 188 | |
Rest of World($M) | 166 | 153 | 182 | 165 | 195 | 179 | 177 | 197 | 192 | 187 | 193 | 180 | |
U. S.($M) | 0 | 0.10 | 0 | 4.90 | 2 | 2.50 | 4.30 | 5 | 4.30 | 11.1 | 3.70 | 7.90 | |
AVONEX($M)2 | 157 | 170 | 163 | 163 | 189 | 178 | 167 | 170 | 176 | 183 | 179 | 206 | |
U. S.($M) | 110 | 121 | 109 | 119 | 133 | 122 | 109 | 107 | 116 | 117 | 111 | 140 | |
Rest of World($M) | 46.6 | 49.1 | 54.7 | 43.3 | 55.1 | 56 | 58.2 | 62.7 | 60.6 | 65.6 | 67.3 | 66.6 | |
Contract manufacturing, royalty and other revenue($M) | 150 | 242 | 247 | 151 | 245 | 293 | 232 | 109 | 182 | ||||
Contract manufacturing revenue($M) | 136 | 232 | 237 | 30.6 | 142 | 225 | 282 | 118 | 222 | 100 | 152 | 105 | |
BENEPALI($M)2 | 117 | 107 | 122 | 108 | 122 | 112 | 111 | 125 | 118 | 117 | 119 | 108 | |
Rest of World($M) | 117 | 107 | 122 | 108 | 122 | 112 | 111 | 125 | 118 | 117 | 119 | 108 | |
U. S.($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Other($M)2 | 84.4 | 70.8 | 55.4 | 55.3 | 46.8 | 29.4 | 24.1 | 17.6 | 15.2 | ||||
U. S.($M) | 83.4 | 70.7 | 55.3 | 55.3 | 46.4 | 28.1 | 22.3 | 15.7 | 13.3 | ||||
Rest of World($M) | 1 | 0.10 | 0.10 | 0 | 0.40 | 1.30 | 1.80 | 1.90 | 1.90 | ||||
ZURZUVAE($M)2 | 84.4 | 70.8 | 55.4 | 65.7 | 55.3 | 46.4 | 27.7 | 22.9 | 22 | 14.9 | 12.4 | 1.60 | |
U. S.($M) | 83.4 | 70.7 | 55.3 | 65.7 | 55.3 | 46.4 | 27.7 | 22.9 | 22 | 14.9 | 12.4 | 1.60 | |
Rest of World($M) | 1 | 0.10 | 0.10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
TECFIDERA($M)2 | 82 | 90.9 | 110 | 112 | 168 | 194 | 206 | 228 | 233 | 252 | 254 | 244 | |
Rest of World($M) | 50.8 | 58.5 | 78.1 | 74.9 | 124 | 146 | 166 | 187 | 193 | 208 | 211 | 181 | |
U. S.($M) | 31.2 | 32.4 | 31.4 | 36.9 | 44.6 | 47.2 | 39.8 | 41.3 | 40.1 | 44.1 | 43.7 | 63.8 | |
Alzheimer's collaboration revenue($M) | 68.4 | 63.7 | 59.5 | 42.7 | 54.9 | 33 | 18.6 | 11.8 | 2.80 | ||||
Alzheimer's Collaboration($M) | 68.4 | 63.7 | 59.5 | 47.1 | 42.7 | 54.9 | 33 | 26.7 | 18.6 | 11.8 | 2.80 | ||
PLEGRIDY($M)2 | 51.6 | 55.1 | 64.3 | 63.2 | 58.4 | 69 | 59.5 | 66 | 61.3 | 68.1 | 65.1 | 73.9 | |
Rest of World($M) | 28.4 | 29.9 | 40 | 38.5 | 30.6 | 40.7 | 35.4 | 39.3 | 33.4 | 39.9 | 36.5 | 43.1 | |
U. S.($M) | 23.2 | 25.2 | 24.3 | 24.7 | 27.8 | 28.3 | 24.1 | 26.7 | 27.9 | 28.2 | 28.6 | 30.8 | |
EMPAVELI($M)2 | 51.5 | 30.4 | 0 | 0 | |||||||||
U. S.($M) | 51.5 | 30.4 | 0 | ||||||||||
Rest of World($M) | 0 | 0 | 0 | ||||||||||
IMRALDI($M)2 | 42 | 37.8 | 49.6 | 43.5 | 52.6 | 46.7 | 47.4 | 51 | 54.1 | 53.2 | 54.8 | 54.5 | |
Rest of World($M) | 42 | 37.8 | 49.6 | 43.5 | 52.6 | 46.7 | 47.4 | 51 | 54.1 | 53.2 | 54.8 | 54.5 | |
U. S.($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
QALSODY($M)2 | 37.5 | 31.9 | 32.5 | 25 | 26.4 | 20 | 15.5 | 11.7 | 11.1 | 5 | 4.60 | 3.30 | |
Rest of World($M) | 26.7 | 23.6 | 22 | 17.2 | 19.1 | 12.5 | 8 | 5.30 | 5.60 | 0.40 | 0.20 | 0 | |
U. S.($M) | 10.8 | 8.30 | 10.5 | 7.80 | 7.30 | 7.50 | 7.50 | 6.40 | 5.50 | 4.60 | 4.40 | 3.30 | |
Royalty and other revenue($M) | 13.8 | 10 | 9.70 | 13.2 | 9.70 | 19.6 | 11 | 12.2 | 9.70 | 9 | 29.6 | 12.8 | |
FLIXABI($M)2 | 6.40 | 8.10 | 10.5 | 9.90 | 15.3 | 14.3 | 13.1 | 16.1 | 16.2 | 13.1 | 17.8 | 16.7 | |
Rest of World($M) | 6.40 | 8.10 | 10.5 | 9.90 | 15.3 | 14.3 | 13.1 | 16.1 | 16.2 | 13.1 | 17.8 | 16.7 | |
U. S.($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
BYOOVIZ($M)2 | 0.20 | 0.10 | 0 | 7.90 | 7 | 8.60 | 8.90 | 9.30 | 8 | 13.7 | 5.60 | 9.20 | |
Rest of World($M) | 0.20 | 0 | 0 | 3.60 | 5 | 6.10 | 4.70 | 4.40 | 3.90 | 3.40 | 1.90 | 1.30 | |
U. S.($M) | 0 | 0.10 | 0 | 4.30 | 2 | 2.50 | 4.20 | 4.90 | 4.10 | 10.3 | 3.70 | 7.90 | |
FAMPYRA($M)2 | 0 | 0 | 0 | 1.10 | 0 | 0 | 0.30 | 14.4 | 19.4 | 18.7 | 19.2 | 23 | |
U. S.($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Rest of World($M) | 0 | 0 | 0 | 1.10 | 0 | 0 | 0.30 | 14.4 | 19.4 | 18.7 | 19.2 | 23 | |
FUMADERM And ADUHELM($M)2 | 0 | 0 | 0 | 0 | 0 | 0.40 | 1.70 | 2.70 | 2.10 | 2.70 | 2.80 | 2.40 | |
Rest of World($M) | 0 | 0 | 0 | 0 | 0 | 0.40 | 1.30 | 1.90 | 1.80 | 1.90 | 1.90 | 1.90 | |
U. S.($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0.40 | 0.80 | 0.30 | 0.80 | 0.90 | 0.50 | |
TOFIDENCE($M)2 | 0 | 0 | 0 | 0.60 | 0 | 0 | 0.10 | 0.10 | 0.20 | 0.80 | 0 | 0 | |
Rest of World($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
U. S.($M) | 0 | 0 | 0 | 0.60 | 0 | 0 | 0.10 | 0.10 | 0.20 | 0.80 | 0 | 0 | |
Growth Portfolio Revenue($M)1 | 1,260 | 1,060 | 851 | ||||||||||
Growth Portfolio Revenue Growth YoY(%) | 49.0% | 24.0% | 12.0% | 6.0% | |||||||||
Total Consolidated Revenue($M)3 | 2,804 | 2,736 | 2,478 | 2,279 | 2,535 | 2,646 | 2,431 | 2,455 | 2,466 | 2,465 | 2,291 | 2,386 | |
Reported Revenue Growth YoY(%) | 10.6% | 3.4% | 1.9% | -7.1% | 2.8% | 7.3% | 6.1% | 2.9% | -2.5% | 0.4% | -7.0% | -6.2% | |
Constant-Currency Revenue Growth YoY(%) | 10.2% | 1.6% | -1.6% | -7.2% | 1.9% | 7.5% | 7.6% | 2.4% | -2.8% | 0.9% | -7.0% | -4.9% | |
Foreign Exchange & Hedging Impact (pp)(%) | 0.4% | 1.8% | 3.5% | 0.1% | 0.9% | -0.2% | -1.5% | 0.5% | 0.3% | -0.5% | 0.0% | -1.3% | |
Total Product Revenue, Net($M)3 | 2,089 | 1,916 | 1,752 | 1,667 | 1,847 | 1,879 | 1,727 | 1,833 | 1,769 | 1,900 | 1,712 | 1,832 | |
Reported Revenue Growth YoY(%) | 13.1% | 2.0% | 1.5% | -9.0% | 4.4% | -1.1% | 0.9% | 0.0% | -2.0% | 4.7% | -2.9% | -3.8% | |
Constant-Currency Revenue Growth YoY(%) | 12.5% | 0.0% | -2.5% | -9.3% | 3.2% | -0.8% | 2.5% | -0.4% | -2.2% | 5.6% | -2.6% | -2.0% | |
Foreign Exchange & Hedging Impact (pp)(%) | 0.6% | 2.0% | 4.0% | 0.3% | 1.2% | -0.3% | -1.6% | 0.4% | 0.2% | -0.9% | -0.3% | -1.8% | |
Revenue from Anti-CD20 Therapeutic Programs($M)5 | 497 | 514 | 419 | 521 | 494 | 467 | 378 | 465 | 446 | 445 | 394 | 436 | |
Share of U.S. Pre-Tax Profits — RITUXAN, GAZYVA & LUNSUMIO($M) | 118 | 126 | 94.7 | 128 | 101 | 108 | 83.7 | 107 | 94.8 | 103 | 87.1 | 94.4 | |
Other Revenue from Anti-CD20 Programs($M) | 9.10 | 6.40 | 7.20 | 7.50 | 6.50 | 5.80 | 5.70 | 4.80 | 4.60 | 4.80 | 4.20 | 3.40 | |
Reported Revenue Growth YoY(%) | 0.7% | 9.9% | 10.8% | 12.0% | 10.7% | 5.1% | -4.0% | 6.7% | 6.0% | 2.6% | |||
Constant-Currency Revenue Growth YoY(%) | 0.7% | 9.8% | 10.7% | 12.0% | 10.7% | 5.1% | -4.0% | 6.7% | 6.0% | 2.5% | |||
Foreign Exchange & Hedging Impact (pp)(%) | 0.0% | 0.1% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | |||
Alzheimer's Collaboration Revenue (Biogen 50% Net Share)($M)3 | 68.4 | 63.7 | 59.5 | 47.1 | 42.7 | 54.9 | 33 | 26.7 | 18.6 | 11.8 | 2.80 | 1.60 | |
Reported Revenue Growth YoY(%) | 60.2% | 16.0% | 80.3% | 129.6% | |||||||||
Constant-Currency Revenue Growth YoY(%) | 60.2% | 16.0% | 80.4% | 129.2% | |||||||||
Foreign Exchange & Hedging Impact (pp)(%) | 0.0% | 0.0% | -0.1% | 0.4% | |||||||||
Contract Manufacturing, Royalty & Other Revenue($M)3 | 150 | 242 | 247 | 43.8 | 151 | 245 | 293 | 130 | 232 | 109 | 182 | 118 | |
Reported Revenue Growth YoY(%) | -1.0% | -0.9% | -15.8% | -66.2% | -34.7% | 124.4% | 61.3% | 11.6% | -17.8% | -31.7% | -38.5% | -38.4% | |
Constant-Currency Revenue Growth YoY(%) | -1.1% | -4.5% | -20.4% | -65.7% | -35.2% | 119.2% | 62.7% | 9.1% | -18.8% | -31.6% | -39.5% | -38.3% | |
Foreign Exchange & Hedging Impact (pp)(%) | 0.1% | 3.6% | 4.6% | -0.5% | 0.5% | 5.2% | -1.4% | 2.5% | 1.0% | -0.1% | 1.0% | -0.1% | |
LEQEMBI Global In-Market Sales (Recorded by Eisai)($M)1 | 202 | 184 | 168 | 134 | 121 | 160 | 96 | 87 | 67 | 40 | 19 | 7 | |
LEQEMBI U.S. In-Market Sales($M) | 107 | 97 | 86 | 78 | 69 | 63 | 52 | 50 | 39 | 30 | |||
LEQEMBI Global Pre-Audit Revenue (Eisai Official, JPY B)(M)3 | 32.2 | 29.3 | 26.2 | 20.7 | 18 | 23.1 | 14.7 | 10 | 6.30 | 2.83 | |||
United States (JPY B)(M) | 17.1 | 15.4 | 13.4 | 11.9 | 10.2 | 9.10 | |||||||
Japan (JPY B)(M) | 6.90 | 6.10 | 6.50 | 6.20 | 6.20 | 5.50 | |||||||
China (JPY B)(M) | 4.90 | 4.80 | 4.10 | 0.40 | 0.20 | 7.70 | |||||||
Biogen 50% Alzheimer's Collaboration Net Revenue($M)3 | 68.4 | 63.7 | 59.5 | 47.1 | 42.7 | 54.9 | 33 | 26.7 | 18.6 | 11.8 | 2.80 | 1.60 | |
LEQEMBI Collaboration SG&A Expense Incurred($M) | 168 | 155 | 170 | 176 | 177 | 171 | 178 | 171 | 165 | 138 | 174 | 113 | |
Accounts Receivable from Collaborator — Eisai($M) | 14.3 | 134 | 7 | 90.2 | 104 | 143 | 116 | 16.7 | 93.2 | 10.3 | 15.9 | 1.40 | |
Accounts Payable to Collaborator — Eisai($M) | 46.7 | 92.5 | 85.4 | 95.5 | 97.9 | 97.5 | 123 | 138 | 146 | 172 | 181 | 118 | |
Rare Disease Product Revenue($M)3 | 676 | 602 | 557 | 515 | 533 | 543 | 563 | 535 | 495 | 534 | 424 | 472 | |
Reported Revenue Growth YoY(%) | 26.8% | 10.8% | -1.1% | -3.9% | 7.8% | 1.7% | 32.9% | 13.5% | 10.0% | -1.8% | -35.0% | -15.5% | |
Constant-Currency Revenue Growth YoY(%) | 26.9% | 8.8% | -4.9% | -3.6% | 6.1% | 2.8% | 35.6% | 14.8% | 9.9% | 0.5% | -35.0% | -11.6% | |
Foreign Exchange & Hedging Impact (pp)(%) | -0.1% | 2.0% | 3.8% | -0.3% | 1.7% | -1.1% | -2.7% | -1.3% | 0.1% | -2.3% | 0.0% | -3.9% | |
Other Product Revenue (Postpartum Depression & Legacy)($M)3 | 84.4 | 70.8 | 55.4 | 65.7 | 55.3 | 46.8 | 29.4 | 25.6 | 24.1 | 17.6 | 15.2 | 4 | |
Reported Revenue Growth YoY(%) | 52.6% | 51.4% | 88.4% | 128.9% | 169.5% | 93.4% | |||||||
Constant-Currency Revenue Growth YoY(%) | 52.6% | 51.4% | 87.4% | 129.7% | 170.4% | 92.3% | |||||||
Foreign Exchange & Hedging Impact (pp)(%) | 0.0% | 0.0% | 1.0% | -0.8% | -0.9% | 1.1% | |||||||
Multiple Sclerosis (MS) Product Revenue($M)3 | 919 | 963 | 958 | 917 | 1,062 | 1,107 | 953 | 1,070 | 1,054 | 1,150 | 1,076 | 1,168 | |
Reported Revenue Growth YoY(%) | -13.4% | -13.0% | 0.5% | -14.3% | 0.7% | -3.7% | -11.4% | -8.4% | -9.1% | 13.4% | -4.4% | -7.9% | |
Constant-Currency Revenue Growth YoY(%) | -13.3% | -14.4% | -2.9% | -15.1% | -0.4% | -3.9% | -10.4% | -9.1% | -9.2% | 13.5% | -4.2% | -6.4% | |
Foreign Exchange & Hedging Impact (pp)(%) | -0.1% | 1.4% | 3.4% | 0.8% | 1.1% | 0.2% | -1.0% | 0.7% | 0.1% | -0.1% | -0.2% | -1.5% | |
Biosimilars Product Revenue($M)3 | 166 | 153 | 182 | 170 | 197 | 182 | 181 | 202 | 197 | 198 | 197 | 188 | |
Reported Revenue Growth YoY(%) | -15.7% | -15.9% | 0.8% | -15.7% | 0.1% | -8.3% | -8.2% | 7.1% | 1.2% | 1.5% | 538.4% | 94.7% | |
Constant-Currency Revenue Growth YoY(%) | -19.2% | -20.0% | -6.5% | -15.1% | -0.3% | -7.6% | -4.9% | 4.1% | 0.2% | 1.0% | 541.6% | 90.0% | |
Foreign Exchange & Hedging Impact (pp)(%) | 3.5% | 4.1% | 7.3% | -0.6% | 0.4% | -0.7% | -3.3% | 3.0% | 1.0% | 0.5% | -3.2% | 4.7% | |
SYFOVRE (Geographic Atrophy) — Continuous Full-Quarter U.S. Net Revenue($M) | 191 | 162 | 151 | 155 | 151 | 151 | 130 | 168 | 152 | 155 | 138 | 114 | |
EMPAVELI (PNH / C3G / IC-MPGN) — Continuous Full-Quarter U.S. Net Revenue($M) | 51.5 | 46 | 41.3 | 35.1 | 26.8 | 20.8 | 19.7 | 23.4 | 24.6 | 24.5 | 25.6 | 24.4 | |
Apellis Standalone Total Revenue (Pre-Acquisition through Q1 2026)($M)3 | 268 | 200 | 459 | 179 | 167 | 213 | 197 | 200 | 172 | 146 | |||
SYFOVRE Pre-Acquisition Net Product Revenue($M) | 151 | 155 | 151 | 151 | 130 | 168 | 152 | 155 | 138 | 114 | |||
EMPAVELI Pre-Acquisition Net Product Revenue($M) | 41.3 | 35.1 | 26.8 | 20.8 | 19.7 | 23.4 | 24.6 | 24.5 | 25.6 | 24.4 | |||
Apellis Ending GTN Product Revenue Reserves($M) | 65.8 | 58.6 | 47.5 | 44.5 | 38.9 | 45.1 | 32.9 | 22.7 | 19.2 | 16.6 | |||
Apellis Standalone Operating Expenses (Pre-Acquisition)($M)7 | 242 | 251 | 235 | 212 | 250 | 239 | 244 | 229 | 234 | 231 | |||
Apellis Standalone R&D Expense($M) | 77 | 74.2 | 68.2 | 67 | 86.4 | 76.3 | 88.6 | 78 | 84.7 | 69.3 | |||
Apellis Standalone SG&A Expense($M) | 124 | 147 | 143 | 131 | 129 | 122 | 122 | 128 | 130 | 142 | |||
Apellis Standalone Operating Income / (Loss)($M) | 26.5 | -51.1 | 223 | -33.3 | -83.3 | -26.2 | -47.3 | -29.4 | -62.1 | -84.5 | |||
Apellis Standalone Net Income / (Loss)($M) | 18.7 | -59 | 216 | -42.1 | -92.2 | -36.4 | -57.5 | -37.7 | -66.4 | -88.6 | |||
Apellis Standalone Operating Cash Flow($M) | -61 | -14.2 | 109 | 4.40 | -53.4 | 19.4 | 34.1 | -8.30 | -133 | -97.9 | |||
Apellis Standalone Cash & Equivalents($M) | 405 | 466 | 479 | 370 | 358 | 411 | 397 | 360 | 326 | 351 | |||
Apellis Standalone Net Inventories($M)3 | 131 | 143 | 123 | 121 | 82.5 | 81.4 | 121 | 153 | 161 | 146 | |||
Raw Materials($M) | 42.1 | 43.3 | 52.2 | 56.4 | 49.9 | 54.4 | 46.6 | 50.5 | 42.1 | 32.7 | |||
Work in Process($M) | 104 | 121 | 108 | 101 | 83.7 | 92.9 | 114 | 117 | 106 | 82.9 | |||
Finished Goods($M) | 13.7 | 13 | 4.10 | 11.5 | 9.50 | 9.90 | 6.80 | 8.80 | 13 | 30.7 | |||
Ending Gross-to-Net (GTN) Product Revenue Reserves($M)5 | 1,291 | 1,243 | 1,177 | 1,211 | 1,322 | 1,271 | 1,170 | 1,092 | 1,151 | 1,116 | 1,097 | 1,062 | |
Contractual Adjustments (Managed Care, Medicaid, Medicare & Chargebacks)($M) | 1,097 | 1,067 | 1,020 | 1,046 | 1,101 | 1,035 | 950 | 881 | 923 | 910 | 903 | 857 | |
Cash Discounts Reserve($M) | 131 | 122 | 105 | 116 | 163 | 176 | 167 | 163 | 186 | 162 | 158 | 173 | |
Product Returns & Allowances Reserve($M) | 62.8 | 54.5 | 51.7 | 49 | 57.8 | 60.3 | 53.8 | 48.1 | 42.5 | 43.5 | 36.4 | 31.6 | |
Recorded as Deduction from Accounts Receivable($M) | 271 | 263 | 216 | 210 | 260 | 274 | 205 | 154 | 151 | 152 | 140 | 136 | |
Recorded in Accrued Expense & Other Current Liabilities($M) | 1,020 | 980 | 961 | 1,000 | 1,062 | 997 | 965 | 938 | 1,000 | 965 | 957 | 927 | |
GTN Provisions Related to Sales in Current Year($M)4 | 975 | 900 | 905 | 957 | 870 | 930 | 881 | 910 | 860 | 896 | 869 | 923 | |
Contractual Adjustments Provision($M) | 739 | 668 | 684 | 721 | 651 | 712 | 690 | 683 | 650 | 673 | 683 | 737 | |
Cash Discounts Provision($M) | 226 | 226 | 214 | 225 | 213 | 208 | 186 | 219 | 206 | 218 | 182 | 182 | |
Product Returns Provision($M) | 9.60 | 6.10 | 7.30 | 11.2 | 5.80 | 9.30 | 5.60 | 8 | 5 | 5.60 | 5 | 4.80 | |
GTN Adjustments Related to Prior-Year Sales($M) | 11.5 | 40.3 | 17.2 | 1.30 | 20.2 | 32.9 | 26.1 | 3.60 | 3.90 | 3.80 | 5.20 | 15.2 | |
GTN Payments & Credits Applied — Current-Year Sales($M)4 | 826 | 672 | 389 | 867 | 734 | 687 | 348 | 830 | 773 | 687 | 371 | 745 | |
Contractual Adjustments Paid (Current-Year Sales)($M) | 614 | 490 | 255 | 635 | 527 | 515 | 230 | 599 | 593 | 536 | 262 | 583 | |
Cash Discounts Applied (Current-Year Sales)($M) | 213 | 183 | 133 | 231 | 207 | 172 | 118 | 231 | 180 | 151 | 109 | 163 | |
Product Returns Applied (Current-Year Sales)($M) | -0.20 | 0 | 0.10 | 1.20 | 0.30 | 0.10 | 0.10 | 0.20 | 0.10 | 0.10 | 0.20 | 0.10 | |
GTN Payments & Credits Applied — Prior-Year Sales($M)3 | 89.4 | 173 | 533 | 200 | 64.2 | 110 | 428 | 136 | 48.4 | 186 | 458 | 173 | |
Contractual Adjustments Paid (Prior-Year Sales)($M) | 81.6 | 124 | 426 | 139 | 38.8 | 80.9 | 360 | 121 | 37.1 | 119 | 358 | 163 | |
Cash Discounts Applied (Prior-Year Sales)($M) | 3.70 | 36.7 | 92.3 | 41.8 | 19.7 | 26.9 | 64.9 | 11.1 | 5 | 61.6 | 94.2 | 5.30 | |
Product Returns Applied (Prior-Year Sales)($M) | 4.10 | 13 | 14.9 | 18.5 | 5.70 | 2.10 | 3.70 | 3.30 | 6.30 | 5.50 | 5.60 | 4.80 | |
Largest Wholesale Distributor — Share of Gross Product Revenue(%)1 | 30.3% | 29.9% | 27.3% | 27.8% | 28.2% | 25.9% | 25.9% | 25.4% | 25.6% | ||||
Second-Largest Wholesale Distributor — Share of Gross Product Revenue(%) | 16.9% | 16.5% | 14.7% | 16.0% | 15.8% | 14.1% | 14.8% | 12.3% | 11.7% | ||||
R&D Expense Excluding Acquired IPR&D (Disaggregated by Stage)($M)5 | 574 | 530 | 539 | 509 | 436 | 399 | 434 | 513 | 516 | 505 | 445 | 554 | |
Late-Stage Clinical Programs (Phase 3 / Registrational)($M) | 176 | 120 | 103 | 77.6 | 60.4 | 44.6 | 49.4 | 74.1 | 56.3 | 46.7 | 32.6 | ||
Early-Stage Clinical Programs (Phase 1 & Phase 2)($M) | 87.1 | 49.3 | 69 | 73.5 | 59.9 | 51.9 | 72.4 | 71.8 | 64.1 | 66.6 | 84.1 | ||
Marketed Products Post-Approval R&D($M) | 113 | 152 | 154 | 128 | 108 | 87.7 | 89.5 | 121 | 126 | 170 | 118 | ||
Research & Discovery Programs($M) | 54.2 | 41.6 | 40.5 | 51.3 | 41 | 46.6 | 44.3 | 59.9 | 48.3 | 45.7 | 47.6 | ||
Other R&D Costs & Infrastructure Overhead($M) | 144 | 167 | 173 | 179 | 167 | 168 | 179 | 187 | 222 | 176 | 163 | ||
Total R&D Including Acquired IPR&D, Upfront & Milestones($M)2 | 284 | 164 | 34 | 2.10 | 46.6 | 201 | 26.5 | 8.50 | 7.50 | ||||
Cash Payments to Acquire In-Process R&D($M) | 225 | 100 | 35 | 50 | 0 | 0 | 0 | ||||||
Discovery & Preclinical Collaboration R&D Expense($M) | 51.3 | 4 | 34 | -6 | 2.10 | 16.6 | 1 | 11.5 | 26.5 | 8.50 | 7.50 | 1.30 | |
Collaboration Profit Sharing / (Loss Reimbursement), Net Expense($M)9 | 77.8 | 68.8 | 74.2 | 69.9 | 87.2 | 75 | 58.1 | 57.1 | 69.3 | 62.4 | 65.6 | 54.3 | |
Samsung Bioepis Biosimilars Profit Sharing($M) | 49 | 44.9 | 57.2 | 47.5 | 66.5 | 57.2 | 48 | 50.6 | 60.3 | 55.9 | 60.6 | 53.1 | |
ZURZUVAE U.S. 50/50 Collaboration Profit Sharing (Sage / Supernus)($M) | 28.8 | 23.9 | 17 | 22.4 | 20.7 | 17.8 | 10.1 | 6.50 | 9 | 6.50 | 5 | -1.20 | |
ZURZUVAE Collaboration R&D Expense Incurred($M) | 1 | 1.20 | 1.20 | 0.50 | -1.70 | 1.50 | 2.40 | 4.60 | 8.40 | 9.60 | 11.6 | 17.8 | |
ZURZUVAE Collaboration SG&A Expense Incurred($M) | 56.4 | 53.3 | 47.5 | 42 | 41.8 | 45.7 | 43.5 | 35.6 | 28.4 | 26.9 | 27.6 | 34.7 | |
Denali Therapeutics Collaboration R&D Expense Incurred($M) | 2.30 | 5.50 | 10.3 | 7.80 | 11.4 | 12.1 | 12.8 | 8.60 | 14.9 | 15.4 | 14.2 | 13.7 | |
Stoke Therapeutics (Zorevunersen) Collaboration R&D Incurred($M) | 28.6 | 14.3 | 12.2 | 39.4 | 9.10 | 8.90 | 3.90 | ||||||
UCB (Dapirolizumab Pegol) Collaboration R&D Incurred($M) | 38.4 | 29.3 | 29.4 | 17.1 | 23.2 | 17.8 | 21.8 | 25.2 | 19.2 | 16.5 | 16.6 | ||
Accrued Royalties Payable (Current)($M) | 348 | 338 | 309 | 302 | 320 | 200 | 167 | 190 | 179 | 193 | 162 | 192 | |
Accrued Collaboration Expenses (Current)($M) | 234 | 199 | 354 | 280 | 269 | 180 | 233 | 309 | 281 | 319 | 278 | 215 | |
Non-GAAP Net Income Attributable to Biogen Inc.($M) | 391 | 536 | 529 | 294 | 708 | 803 | 443 | 502 | 596 | 771 | 535 | 430 | |
Non-GAAP Diluted Earnings Per Share($)1 | 2.62 | 3.60 | 3.57 | 1.99 | 4.81 | 5.47 | 3.02 | 3.44 | 4.08 | 5.28 | 3.67 | 2.95 | |
Net Non-GAAP Adjustments per Diluted Share($) | 2.76 | 2.94 | 1.42 | 2.32 | 1.64 | 1.14 | 1.38 | 1.61 | 1.42 | 1.28 | 0.97 | 1.24 | |
Non-GAAP Cost of Sales (Excl. Acquired Intangible Amortization)($M)1 | 553 | 612 | 610 | 510 | 554 | 580 | 593 | 504 | 500 | 587 | |||
Acquisition Inventory Fair Value Step-Up Amortization (COGS)($M) | 195 | 164 | 49.7 | 0 | 0 | 49.4 | 46.1 | 42.3 | 42.2 | ||||
Non-GAAP Research & Development Expense($M) | 567 | 490 | 480 | 432 | 394 | 427 | 491 | 464 | 447 | 568 | |||
Non-GAAP Selling, General & Administrative Expense($M) | 730 | 680 | 600 | 592 | 579 | 572 | 556 | 542 | 569 | 588 | |||
Non-GAAP Amortization & Impairment of Acquired Intangibles($M)1 | 12.6 | 14.6 | 13.4 | 13.9 | 12.8 | 10.5 | 11.8 | 10.8 | 9.50 | 9.40 | |||
GAAP Acquired Intangible Amortization Excluded from Non-GAAP($M) | 160 | 154 | 123 | 122 | 115 | 101 | 98.3 | 76.1 | 68.8 | 67.2 | |||
Non-GAAP Other Expense, Net($M) | 91.4 | 60.1 | 42 | 43.6 | 56.6 | 32.8 | 53.9 | 54.6 | 63 | 62.3 | |||
Non-GAAP Income Tax Expense($M)2 | 97.9 | 111 | 95.3 | 147 | 125 | 107 | 95 | 146 | 101 | 87.9 | |||
Non-GAAP Effective Tax Rate(%) | 20.0% | 17.2% | 15.3% | 10.1% | 17.2% | 13.5% | 19.4% | 12.2% | 13.8% | 15.9% | 15.9% | 17.0% | |
GAAP Effective Tax Rate(%) | -128.5% | 26.4% | 15.4% | 12.8% | 16.3% | 14.7% | 22.7% | 8.5% | 13.9% | 16.5% | 15.4% | 14.7% | |
Non-GAAP Free Cash Flow($M) | 600 | 408 | 594 | 468 | 1,226 | 134 | 222 | 722 | 901 | 592 | 507 | -52.7 | |
Contingent Consideration Liabilities — Total Level 3 Fair Value($M)3 | 270 | 269 | 267 | 246 | 391 | 535 | 522 | 513 | 509 | 0 | |||
Contingent Consideration Liabilities — Noncurrent($M) | 122 | 274 | 267 | 246 | 243 | 238 | 228 | 222 | 222 | ||||
Contingent Consideration Fair Value Remeasurement Loss / (Gain)($M) | 0.40 | 2.50 | 20.5 | 5.60 | 13.2 | 9.60 | 23.8 | 0 | 0 | ||||
Level 3 Valuation — Weighted-Average Discount Rate(%) | 6.9% | 5.9% | 5.7% | 5.4% | 5.4% | 5.7% | 5.9% | 6.2% | 5.6% | ||||
Total Restructuring Charges($M)3 | 66.5 | 165 | 7.90 | 6.60 | 7.40 | -0.70 | 35.3 | 5.30 | 6.80 | 6.60 | 11.5 | 98.8 | |
Workforce Reduction Severance Charges($M) | 66.5 | 165 | 7.90 | 7.40 | -0.70 | 35.3 | |||||||
Workforce Reduction Restructuring Reserve Balance($M) | 66.8 | 35.9 | 13.6 | 15.8 | 19.2 | 29.2 | 40.4 | 31.9 | 75.4 | ||||
Workforce Reduction Restructuring Cash Payments($M) | 35.8 | 143 | 10.3 | 17.4 | 9.50 | 25.8 | |||||||
Litigation Settlement & Loss Contingency Charges($M) | 30.8 | -0.40 | 4.70 | 131 | 0.80 | 5.20 | 3 | 3.90 | |||||
Inventories, Net (Current)($M)5 | 2,224 | 2,384 | 1,949 | 2,168 | 2,209 | 2,274 | 2,274 | 2,461 | 2,469 | 2,506 | 2,517 | 2,527 | |
Raw Materials($M) | 321 | 308 | 279 | 293 | 296 | 305 | 306 | 318 | 369 | 401 | 413 | 427 | |
Work in Process (WIP)($M) | 1,538 | 1,655 | 1,352 | 1,595 | 1,635 | 1,642 | 1,717 | 1,883 | 1,804 | 1,821 | 1,851 | 1,927 | |
Finished Goods($M) | 499 | 557 | 458 | 425 | 441 | 478 | 368 | 354 | 391 | 395 | 348 | 255 | |
Long-Term Inventories (Included in Other Noncurrent Assets)($M) | 133 | 136 | 140 | 145 | 162 | 151 | 117 | 93.9 | 94.5 | 111 | 94.9 | 81.7 | |
Inventory Excess & Obsolescence Write-Downs($M) | 9.30 | 5.10 | 4.80 | 15.3 | -0.40 | 7 | 7.30 | 33.2 | 24.3 | 16.9 | 27.5 | 62.3 | |
Finite-Lived Acquired Intangible Assets, Net($M)10 | 11,549 | 11,716 | 7,255 | 7,380 | 7,529 | 7,664 | 7,778 | 7,884 | 7,959 | 8,029 | 8,081 | 5,859 | |
Finite-Lived Intangible Assets, Gross($M) | 18,714 | 18,709 | 14,079 | 14,067 | 14,087 | 14,087 | 14,104 | 14,138 | 14,102 | 14,064 | 14,029 | 11,729 | |
Finite-Lived Intangible Accumulated Amortization($M) | 7,165 | 6,992 | 6,824 | 6,688 | 6,559 | 6,423 | 6,326 | 6,254 | 6,143 | 6,035 | 5,948 | 5,870 | |
Indefinite-Lived In-Process R&D (IPR&D) Assets($M) | 1,667 | 1,636 | 1,635 | 1,635 | 1,639 | 1,639 | 1,643 | 1,643 | 1,683 | 40 | 40 | 2,340 | |
Indefinite-Lived Trademarks & Trade Names($M) | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | 64 | |
Priority Review Vouchers (Indefinite-Lived)($M) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
Estimated Intangible Amortization — Year 1 / Next 12M($M) | 660 | 665 | 485 | 485 | 485 | 565 | 560 | 525 | 510 | 565 | 565 | 345 | |
Estimated Intangible Amortization — Year 2($M) | 720 | 735 | 525 | 485 | 490 | 600 | 600 | 560 | 550 | 660 | 660 | 470 | |
Estimated Intangible Amortization — Year 3($M) | 830 | 815 | 575 | 525 | 525 | 630 | 630 | 600 | 585 | 680 | 685 | 485 | |
Estimated Intangible Amortization — Year 4($M) | 940 | 925 | 650 | 575 | 580 | 665 | 665 | 630 | 615 | 710 | 710 | 480 | |
Estimated Intangible Amortization — Year 5($M) | 1,045 | 1,025 | 700 | 645 | 650 | 700 | 700 | 665 | 655 | 720 | 715 | 495 | |
Long-Term Debt Principal Maturities — After Year 51 | |||||||||||||
Common Shares Held in Treasury (Millions)(M) | -23.8 | -23.8 | -23.8 | -23.8 | -23.8 | -23.8 | -23.8 | -23.8 | -23.8 | -23.8 | -23.8 | 23.8 | |
U.S. Personal Consumption Expenditures: Health Care (SAAR, $B)(M) | 3,859 | 3,790 | 3,700 | 3,667 | 3,615 | 3,530 | 3,465 | 3,418 | 3,358 | 3,288 | 3,244 | 3,159 | |
Total Revenue (GAAP)($M)14 | 2,804 | 2,736 | 2,478 | 2,279 | 2,535 | 2,646 | 2,431 | 2,455 | 2,466 | 2,465 | 2,291 | 2,386 | |
Cost of Sales (Excl. Acquired Intangible Amortization)($M) | 748 | 777 | 661 | 496 | 674 | 605 | 629 | 584 | 639 | 546 | 542 | 618 | |
Research & Development Expense($M) | 574 | 530 | 539 | 509 | 436 | 399 | 434 | 513 | 516 | 505 | 445 | 554 | |
Selling, General & Administrative Expense($M) | 752 | 710 | 607 | 683 | 595 | 584 | 573 | 680 | 588 | 554 | 582 | 609 | |
Restructuring Charges($M) | 66.5 | 165 | 7.90 | 6.60 | 7.40 | -0.70 | 35.3 | 5.30 | 6.80 | 6.60 | 11.5 | 98.8 | |
Total Cost & Expenses($M) | 2,813 | 2,604 | 2,100 | 2,335 | 1,977 | 1,902 | 2,120 | 2,163 | 2,015 | 1,766 | 1,826 | 2,095 | |
Interest Income($M) | 9.30 | 25.3 | 37.9 | 37.2 | 31.6 | 32.3 | 23.9 | 18.5 | 11.6 | 20.1 | 17.4 | 23.8 | |
Interest Expense($M) | 87.5 | 82.3 | 67.6 | 67.5 | 67.4 | 72.6 | 60 | 60 | 59.8 | 61.3 | 69.2 | 71.5 | |
Income Before Income Taxes($M) | -9 | 132 | 378 | -56 | 557 | 744 | 311 | 292 | 451 | 699 | 465 | 292 | |
Income Tax Expense / (Benefit)($M) | 11.6 | 34.9 | 58.2 | -7.10 | 90.8 | 109 | 70.7 | 24.8 | 62.5 | 115 | 71.4 | 42.7 | |
Net Income / (Loss) Attributable to Biogen Inc.($M) | -20.6 | 97.5 | 320 | -48.9 | 467 | 635 | 241 | 267 | 389 | 584 | 393 | 250 | |
Diluted Earnings / (Loss) Per Share (GAAP)($) | -0.14 | 0.66 | 2.15 | 3.17 | 4.33 | 1.64 | 2.66 | 4 | 2.70 | ||||
Basic Earnings / (Loss) Per Share (GAAP)($) | -0.14 | 0.66 | 2.17 | 3.18 | 4.33 | 1.65 | 2.67 | 4.01 | 2.71 | ||||
Weighted-Average Diluted Shares(M) | 148 | 149 | 148 | 147 | 147 | 147 | 146 | 146 | 146 | ||||
Weighted-Average Basic Shares(M) | 148 | 148 | 147 | 147 | 147 | 146 | 146 | 146 | 145 | ||||
Total Assets($M)12 | 32,054 | 32,087 | 29,483 | 29,440 | 29,208 | 28,330 | 28,033 | 28,049 | 28,313 | 26,804 | 26,568 | 26,845 | |
Cash & Cash Equivalents($M) | 1,304 | 1,285 | 3,383 | 3,009 | 3,863 | 2,759 | 2,598 | 2,375 | 1,699 | 1,909 | 1,074 | 1,050 | |
Inventories, Net($M) | 2,224 | 2,384 | 1,949 | 2,168 | 2,209 | 2,274 | 2,274 | 2,461 | 2,469 | 2,506 | 2,517 | 2,527 | |
Total Current Assets($M) | 7,584 | 7,306 | 9,190 | 8,974 | 8,937 | 7,968 | 7,626 | 7,457 | 6,831 | 7,109 | 6,756 | 6,859 | |
Property, Plant & Equipment, Net($M) | 2,968 | 2,994 | 3,018 | 3,055 | 3,076 | 3,099 | 3,132 | 3,181 | 3,211 | 3,249 | 3,275 | 3,310 | |
Operating Lease Right-of-Use Assets($M) | 176 | 246 | 251 | 265 | 331 | 335 | 346 | 356 | 380 | 389 | 428 | 420 | |
Goodwill($M) | 6,993 | 6,991 | 6,489 | 6,491 | 6,491 | 6,493 | 6,477 | 6,479 | 6,486 | 6,227 | 6,227 | 6,219 | |
Acquired Intangible Assets, Net($M) | 13,380 | 13,516 | 9,054 | 9,179 | 9,332 | 9,468 | 9,585 | 9,691 | 9,806 | 8,233 | 8,285 | 8,363 | |
Total Current Liabilities($M) | 3,898 | 3,917 | 2,999 | 3,349 | 3,290 | 3,184 | 5,297 | 5,529 | 5,425 | 3,108 | 3,223 | 3,434 | |
Total Liabilities($M) | 13,132 | 13,239 | 10,831 | 11,183 | 11,000 | 10,696 | 11,054 | 11,333 | 11,954 | 10,915 | 11,355 | 12,045 | |
Retained Earnings($M) | 20,949 | 20,970 | 20,872 | 20,553 | 20,602 | 20,135 | 19,500 | 19,260 | 18,993 | 18,605 | 18,021 | 17,628 | |
Treasury Stock, at Cost($M) | -2,977 | -2,977 | -2,977 | -2,977 | -2,977 | -2,977 | -2,977 | -2,977 | -2,977 | -2,977 | -2,977 | -2,977 | |
Total Stockholders' Equity($M) | 18,922 | 18,848 | 18,652 | 18,257 | 18,208 | 17,634 | 16,979 | 16,716 | 16,359 | 15,889 | 15,213 | 14,799 | |
Net Cash Flow from Operating Activities($M)5 | 641 | 449 | 646 | 512 | 1,273 | 161 | 259 | 761 | 936 | 626 | 553 | 12.5 | |
Depreciation & Amortization($M) | 241 | 236 | 204 | 200 | 202 | 194 | 183 | 184 | 183 | 159 | 148 | 140 | |
Share-Based Compensation Expense($M) | 81.5 | 77.4 | 84 | 59.6 | 75.3 | 74.9 | 81 | 75.1 | -75 | -72.9 | 72.8 | 54.9 | |
Capital Expenditures (Purchases of PP&E)($M) | 40.4 | 40.9 | 51.2 | 43.9 | 46.2 | 26.6 | 37.1 | 39.3 | 35 | 33.5 | 45.9 | 65.2 | |
Net Cash Flow from Investing Activities($M) | -222 | -3,839 | -210 | -1,232 | -35.1 | -57 | -47.3 | -18.6 | -1,181 | 467 | -66 | -652 | |
Net Cash Flow from Financing Activities($M) | -394 | 1,296 | -43.8 | -137 | -130 | -11.7 | -23 | 7.90 | -6.60 | -245 | -440 | -646 | |
25 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & segment structure: Biogen Inc. reports on a calendar fiscal year ending December 31 (latest quarter: Q3 2026 ended September 30, 2026; latest annual filing: FY2025 ended December 31, 2025). Because Biogen operates as a single global biopharmaceutical reportable segment, commercial performance is tracked across therapeutic franchises (Rare Disease, Multiple Sclerosis, Specialized Immunology, Biosimilars, Other), individual medicines split by U.S. and Rest of World, Anti-CD20 royalties/profit share, and the 50/50 Eisai Alzheimer's collaboration.
- LEQEMBI in-market vs. GAAP collaboration accounting (Group 2): Lead collaboration partner Eisai Co., Ltd. books global commercial product sales of LEQEMBI ($202.0M global and $107.0M U.S. in Q3 2026; JPY 32.2B global across U.S. JPY 17.1B, Japan JPY 6.9B, and China JPY 4.9B in Jul–Sep 2026), whereas Biogen's GAAP income statement records only Biogen's 50% net share of revenue less cost of sales and royalties ($68.4M in Q3 2026).
- Acquisition of Apellis Pharmaceuticals, Inc. (Group 5): On May 14, 2026, Biogen completed the $5.3B acquisition of Apellis Pharmaceuticals, Inc. (CIK 0001492422), adding SYFOVRE (geographic atrophy) and EMPAVELI (PNH, C3G, primary IC-MPGN) as the new Specialized Immunology franchise. Group 5 presents both Apellis's standalone pre-merger SEC disclosures through Q1 2026 and the unbroken full-quarter U.S. net revenue trajectory bridging Q2 2026 ($162.0M full quarter vs. $97.4M post-close in Biogen GAAP for SYFOVRE; $46.0M full quarter vs. $30.4M post-close for EMPAVELI) into Q3 2026 ($191.3M and $51.5M).
- Methodology & calculations: No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. Every cell reflects published figures (with verbatim excerpts shown on hover for text-extracted metrics); the only arithmetic applied in table cells is period splitting from cumulative year-to-date filings (Q4 = full year − 9M; quarter = YTD − prior YTD), shown in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (7)
- Contingent Consideration, Fit for Growth Restructuring & Litigation › Contingent Consideration Liabilities — Total Level 3 Fair Value › Contingent Consideration Liabilities — Current — fewer than 3 consecutive latest periods
- Contingent Consideration, Fit for Growth Restructuring & Litigation › Total Restructuring Charges › Fit for Growth Cumulative Positions Eliminated Target — fewer than 3 consecutive latest periods
- Consolidated Financial Statements (GAAP Reference) › Total Revenue (GAAP) › Gross Profit — fewer than 3 consecutive latest periods
- SYFOVRE commercial & free-goods doses delivered (Apellis pre-merger Form 8-K updates) — Discontinued after Q4 2025; post-acquisition Biogen reports YoY commercial injection volume growth % rather than absolute dose shipments.
- SYFOVRE commercial injection volume growth YoY % (+13% in Q2 2026; +18% in Q3 2026) — Only 2 consecutive post-acquisition quarters published through Q3 2026 (minimum 3 required).
- Cumulative patients treated worldwide ('more than 2 million patients from 1996 through 2025', SASB HC-BP-000.A) — Excluded because only disclosed as an open-ended bound ('more than').
- Point-in-time SPINRAZA high-dose conversion rate ('70% of 12 mg patients with start forms submitted and 50% dosed', Q3 2026 call) — Single-quarter launch commentary without a 3-quarter continuous series.
Dữ liệu cập nhật 2026-11-10.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Core Growth Portfolio & Revenue Architecture
- Growth Portfolio Revenue ($M)3 kỳ
- Total Consolidated Revenue ($M)19 kỳ
- Total Product Revenue, Net ($M)39 kỳ
- Revenue from Anti-CD20 Therapeutic Programs ($M)39 kỳ
- Alzheimer's Collaboration Revenue (Biogen 50% Net Share) ($M)14 kỳ
- Contract Manufacturing, Royalty & Other Revenue ($M)39 kỳ
- Geographic Long-Lived Assets (PP&E & Operating Lease ROU) ($M)4 kỳ
LEQEMBI Global In-Market Franchise & Eisai 50/50 Collaboration
Rare Disease & Postpartum Depression Portfolios
Multiple Sclerosis (MS) & Biosimilars Franchises
Apellis Pharmaceuticals, Inc. (Acquired May 2026 — Specialized Immunology)
- SYFOVRE (Geographic Atrophy) — Continuous Full-Quarter U.S. Net Revenue ($M)15 kỳ
- EMPAVELI (PNH / C3G / IC-MPGN) — Continuous Full-Quarter U.S. Net Revenue ($M)19 kỳ
- Apellis Standalone Total Revenue (Pre-Acquisition through Q1 2026) ($M)20 kỳ
- Apellis Standalone Operating Expenses (Pre-Acquisition) ($M)21 kỳ
U.S. Drug Pricing, Gross-to-Net (GTN) Reserves & Wholesalers
- U.S. Portfolio Weighted-Average Net Price Change YoY (%)3 kỳ
- Ending Gross-to-Net (GTN) Product Revenue Reserves ($M)47 kỳ
- GTN Provisions Related to Sales in Current Year ($M)35 kỳ
- GTN Payments & Credits Applied — Current-Year Sales ($M)35 kỳ
- Largest Wholesale Distributor — Share of Gross Product Revenue (%)30 kỳ
R&D by Clinical Stage, Pipeline & Strategic Collaborations
GAAP to Non-GAAP Operating Reconciliations
- Non-GAAP Net Income Attributable to Biogen Inc. ($M)27 kỳ
- Non-GAAP Diluted Earnings Per Share ($)27 kỳ
- Non-GAAP Cost of Sales (Excl. Acquired Intangible Amortization) ($M)14 kỳ
- Non-GAAP Research & Development Expense ($M)17 kỳ
- Non-GAAP Selling, General & Administrative Expense ($M)25 kỳ
- Non-GAAP Amortization & Impairment of Acquired Intangibles ($M)25 kỳ
- Non-GAAP Other Expense, Net ($M)20 kỳ
- Non-GAAP Income Tax Expense ($M)25 kỳ
- Non-GAAP Free Cash Flow ($M)25 kỳ
Contingent Consideration, Fit for Growth Restructuring & Litigation
Manufacturing Footprint, Inventories, Intangibles & Obligations
Workforce, Executive Compensation, Quality & Sustainability (ESG)
U.S. Pharmaceutical & Healthcare Industry Benchmarks (FRED)
- U.S. PPI: Pharmaceutical Preparation Manufacturing (Index Jun 1981=100) (×)129 kỳ
- U.S. CPI: Medical Care Commodities (Index 1982-84=100, SA) (×)128 kỳ
- U.S. Retail Sales: Pharmacies & Drug Stores (Seasonally Adjusted) ($M)128 kỳ
- U.S. Retail Sales: Pharmacies & Drug Stores (Not Seasonally Adjusted) ($M)128 kỳ
- U.S. Personal Consumption Expenditures: Health Care (SAAR, $B) (M)43 kỳ
Consolidated Financial Statements (GAAP Reference)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Biogen
- Biogen Form 10-Q (filed 2026-10-28) ↗
- Biogen Form 10-K (filed 2026-02-06) ↗
- Biogen Form 8-K (filed 2026-10-28) ↗
- Biogen Form 8-K (filed 2024-02-13) ↗
- Biogen 2025 Corporate Responsibility Report ↗
- Biogen Form 8-K (filed 2026-02-06) ↗
- Apellis Form 10-K (filed 2026-02-24) ↗
- Apellis Form 10-Q (filed 2026-05-07) ↗
- Eisai Co., Ltd. LEQEMBI Release (news202659) ↗
- Federal Reserve Economic Data (PCU325412325412) ↗
- Federal Reserve Economic Data (CUSR0000SAM1) ↗
- Federal Reserve Economic Data (MRTSSM44611USS) ↗
See a number that looks wrong?